Advances in antibody-drug conjugate (ADC) technology and identification of new antigen targets are repositioning ADCs as a promising therapeutic platform for metastatic castration-resistant prostate cancer (mCRPC). This review summarizes recent progress in ADC payload and linker chemistry, highlights membrane antigens in prostate cancer that have demonstrated encouraging antitumor activity in clinical trials, and addresses strategies to mitigate off-target toxicity. These advances position ADCs to transform the therapeutic landscape of mCRPC.
NPJ precision oncology. 2025 Nov 14*** epublish ***
Claire Lin, Matthew J Hadfield, Ariana Santopietro, Galina Lagos, Liang Cheng, Wafik S El-Deiry, Rahul Aggarwal, Anthony Mega, Elias Hyams, Benedito A Carneiro
The Warren Alpert Medical School, Brown University, Providence, RI, USA., Brown University Health, Division of Hematology/Oncology, Department of Medicine, The Warren Alpert Medical School, Providence, RI, USA., Department of Pathology, Brown University, Providence, RI, USA., Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, RI, USA., Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Department of Urology, Brown University, Providence, RI, USA., Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, RI, USA. .